切换至 "中华医学电子期刊资源库"

中华肺部疾病杂志(电子版) ›› 2026, Vol. 19 ›› Issue (05) : 721 -730. doi: 10.3877/cma.j.issn.1674-6902.2026.05.002

论著

肺动脉高压中铁死亡-铜死亡耦合异常及其介导肺血管免疫微环境重塑的机制研究
郭培培1, 吴盛旺2, 马昊昱3,†(), 张静3,†()   
  1. 1400037 重庆,陆军(第三)军医大学第二附属医院检验科
    2400037 重庆,陆军(第三)军医大学第二附属医院血液病医学中心
    3400037 重庆,陆军(第三)军医大学第二附属医院呼吸内科
  • 收稿日期:2026-06-21 出版日期:2026-10-25
  • 通信作者: 马昊昱, 张静
  • 基金资助:
    国家自然科学青年基金项目(82500076)

Ferroptosis-cuproptosis crosstalk and its role in pulmonary vascular immune microenvironment remodeling in pulmonary arterial hypertension

Peipei Guo1, Shengwang Wu2, Haoyu Ma3,†(), Jing Zhang3,†()   

  1. 1Department of Laboratory Medicine, Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
    2Medical Center of Hematology, Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
    3Department of respiratory, Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
  • Received:2026-06-21 Published:2026-10-25
  • Corresponding author: Haoyu Ma, Jing Zhang
引用本文:

郭培培, 吴盛旺, 马昊昱, 张静. 肺动脉高压中铁死亡-铜死亡耦合异常及其介导肺血管免疫微环境重塑的机制研究[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(05): 721-730.

Peipei Guo, Shengwang Wu, Haoyu Ma, Jing Zhang. Ferroptosis-cuproptosis crosstalk and its role in pulmonary vascular immune microenvironment remodeling in pulmonary arterial hypertension[J/OL]. Chinese Journal of Lung Diseases(Electronic Edition), 2026, 19(05): 721-730.

目的

探讨肺动脉高压(pulmonary arterial hypertension, PAH)中铁死亡-铜死亡耦合转录特征及其与肺血管免疫微环境重塑的关系。

方法

基于基因表达综合数据库(Gene Expression Omnibus, GEO)数据库获取PAH相关bulk转录组及单细胞RNA测序数据,采用差异表达分析筛选PAH(n=76)与正常肺组织间差异(n=42)表达基因,并通过单样本基因集富集分析(single-sample Gene Set Enrichment Analysis, ssGSEA)、基因集变异分析(gene set variation analysis, GSVA)计算铁死亡评分、铜死亡评分及铁死亡-铜死亡交叉评分。将PAH差异表达基因、铁-铜死亡相关基因及交叉评分相关基因取交集,筛选候选耦合基因,并进一步进行表达验证、相关性分析及GO、KEGG功能富集分析。基于单细胞数据进行细胞类型注释,分析不同细胞群中铁死亡-铜死亡评分及核心基因的分布特征,并采用CellChat评估PAH肺组织中细胞通讯变化。进一步通过PAH动物模型(n=40),采用血流动力学检测、qRT-PCR和Western blot验证关键分子表达及血流动力学表型。

结果

PAH肺组织中铁死亡、铜死亡及二者交叉相关转录特征发生显著改变,PAH组铁死亡评分、铜死亡评分及铁死亡-铜死亡交叉评分均较正常组显著降低(P=5.3×105、P=0.028、P=0.00029),且铁死亡评分与铜死亡评分呈正相关(R=0.42,P=0.019)。交集分析共获得16个候选基因,进一步筛选获得DLAT、SAT1、MTF1、SLC7A11、GCLM和NCOA4等铁死亡-铜死亡耦合核心候选基因(PAH组DLAT表达上调,其余5个基因表达下调,P分别为8.8×106、2.0×104、3.5×104、0.0073、6.7×105和7.3×104),其功能主要富集于铁死亡7个基因、硫辛酸代谢4个、谷胱甘肽代谢3个、半胱氨酸和蛋氨酸代谢2个等通路。单细胞分析显示(n=9),共注释出16种细胞类型,铁死亡-铜死亡交叉评分在肺血管内皮细胞、平滑肌细胞和巨噬细胞中呈细胞类型特异性变化(log2FC>0.3,min.pct>0.25),PAH组上述三类细胞的交叉评分均显著低于正常组(P分别<0.05、<0.01和<0.05)。细胞通讯分析提示,PAH组细胞间互作数量由2067增加至2802、互作强度由32.759升高至58.673,巨噬细胞与内皮细胞、成纤维细胞及平滑肌细胞之间的THBS1-CD47、SELPLG-SELE、PECAM1-PECAM1和PPIA-BSG等通讯轴增强。动物实验显示,PAH模型组右心室收缩压(对照组约23 mmHg,PAH组约49 mmHg,P<0.01)和Fulton指数(对照组约0.23,PAH组约0.42,P<0.001)显著升高;同时DLATmRNA及蛋白表达上调(P<0.0001、P<0.001),而SAT1、MTF1、SLC7A11、GCLM和NCOA4表达下调(P<0.05)。

结论

PAH肺组织中存在铁死亡-铜死亡耦合异常,该异常主要涉及肺血管内皮细胞、平滑肌细胞和巨噬细胞,并可能通过调控谷胱甘肽代谢、硫辛酸代谢及巨噬细胞-血管壁细胞通讯参与肺血管重塑。

Objective

To investigate ferroptosis-cuproptosis crosstalk in pulmonary arterial hypertension (PAH) and its potential association with pulmonary vascular immune microenvironment remodeling.

Methods

PAH-related bulk transcriptomic and single-cell RNA sequencing datasets were obtained from the GEO database. Differentially expressed genes between PAH(n=76) and normal lung tissues(n=42) were identified, and ferroptosis, cuproptosis and ferroptosis-cuproptosis crosstalk scores were calculated using ssGSEA/GSVA. Candidate crosstalk genes were screened by intersecting PAH differentially expressed genes, ferroptosis/cuproptosis-related genes and crosstalk score-related genes, followed by expression validation, correlation analysis and GO/KEGG functional enrichment analysis. Single-cell RNA sequencing data were further used for cell annotation, cell type-specific score evaluation and core gene distribution analysis. Cell Chat was applied to assess intercellular communication changes in PAH lung tissues. In addition, a PAH animal model(n=40) was used to validate hemodynamic alterations, key molecular expression by qRT-PCR and Western blot.

Results

Ferroptosis-, cuproptosis- and crosstalk-related transcriptional features were markedly altered in PAH lung tissues: the ferroptosis, cuproptosis and crosstalk scores were all significantly lower in PAH than in normal lungs (P=5.3×105, 0.028 and 0.00029, respectively), and ferroptosis score was positively correlated with cuproptosis score (R=0.42, P=0.019). Sixteen candidate genes were obtained by intersection analysis, among which DLAT, SAT1, MTF1, SLC7A11, GCLM and NCOA4 were identified as core candidate genes involved in ferroptosis-cuproptosis crosstalk (DLAT was upregulated whereas the other five genes were downregulated in PAH; P=8.8×106, 2.0×104, 3.5×104, 0.0073, 6.7×105 and 7.3×104, respectively). Functional enrichment analysis showed that these genes were mainly enriched in ferroptosis 7 genes, lipoic acid metabolism 4 genes, glutathione metabolism 3 genes, and cysteine and methionine metabolism 2 genes. Single-cell analysis (n=9) identified 16 cell types and revealed cell type-specific alterations of the crosstalk score in pulmonary vascular endothelial cells, smooth muscle cells and macrophages, all of which showed significantly lower crosstalk scores in PAH (P<0.05, P<0.01 and P<0.05, respectively). CellChat analysis showed increased interaction number (2 067 vs. 2 802) and interaction strength (32.759 vs. 58.673) in PAH, with enhanced macrophage communication with endothelial cells, fibroblasts and smooth muscle cells through signaling axes including THBS1-CD47, SELPLG-SELE, PECAM1-PECAM1 and FN1-(ITGA5+ ITGB1). Animal experiments showed significantly increased right ventricular systolic pressure (approximately 23 vs. 49 mmHg, P<0.01) and Fulton index (approximately 0.23 vs. 0.42, P<0.001) in the PAH group. Moreover, DLAT was upregulated at both mRNA and protein levels (P<0.0001 and P<0.001), whereas SAT1, MTF1, SLC7A11, GCLM and NCOA4 were downregulated (P<0.05).

Conclusion

Ferroptosis-cuproptosis crosstalk is dysregulated in PAH lung tissues and mainly involves pulmonary vascular endothelial cells, smooth muscle cells and macrophages. This dysregulation may participate in pulmonary vascular remodeling by regulating glutathione metabolism, lipoic acid metabolism and macrophage-vascular wall cell communication.

图1 PAH肺组织中铁死亡-铜死亡耦合转录特征显著失调。图A为基于铁死亡、铜死亡及铁-铜死亡交叉相关基因表达谱对正常组与PAH组样本进行PCA分析,并展示主要贡献基因;图B为PAH组与正常组差异表达火山图,突出标注铁死亡、铜死亡及铁-铜死亡交叉相关差异基因,上方展示上调和下调基因的代表性功能富集条目;图C为铁死亡评分与铜死亡评分的相关性分析;图D为正常组与PAH组铁死亡评分、铜死亡评分及铁死亡-铜死亡交叉评分的组间比较
图2 铁死亡-铜死亡耦合核心基因筛选及功能网络构建。图A为PAH差异表达基因、铁-铜死亡相关基因及铁-铜死亡交叉相关基因的Venn交集分析;图B为候选交集基因在正常组与PAH组中的表达热图及层次聚类;图C为核心候选基因DLAT、SAT1、MTF1、SLC7A11、GCLM和NCOA4在正常组与PAH组中的表达差异(图中数值为P值);图D为核心候选基因与铁死亡评分、铜死亡评分及铁-铜死亡交叉评分的相关性热图注:a为P<0.05;b为P<0.01;c为P<0.001
图3 PAH与铁死亡-铜死亡单细胞分析。图A为正常组与PAH组样本中各细胞类型的UMAP分布;图B为正常组与PAH组主要细胞类型组成比例比较;图C为PAEC、PASMC和巨噬细胞中铁死亡-铜死亡交叉评分在正常组与PAH组间的差异比较注:a为P<0.05;b为P<0.01
图4 PAH与铁死亡-铜死亡细胞通讯。图A为正常组与PAH组细胞间通讯互作数量及互作强度比较;图B为正常组与PAH组之间差异互作数量及差异互作强度的细胞通讯网络图;图C为不同细胞亚群作为信号发送者和接受者时的差异互作数量及互作强度热图;图D为PAH组中增强的主要配体-受体通讯轴及其对应细胞互作关系注:a为P<0.05;b为P<0.01
图5 PAH动物模型中血流动力学异常及铁死亡-铜死亡耦合核心基因表达验证。图A为qRT-PCR检测铁死亡-铜死亡耦合核心基因在正常组与PAH组肺组织中的mRNA表达水平;图B为DLAT、SAT1、MTF1、SLC7A11、GCLM和NCOA4蛋白表达的Western blot条带图;图C为Western blot检测上述核心分子在正常组与PAH组肺组织中的相对蛋白表达水平注:a为P<0.05;b为P<0.01;c为P<0.001;d为P<0.0001
1
中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组,等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志,2021, 101(1): 11-51.
2
肺动脉高压筛查诊断与治疗专家共识[J]. 中华心血管病杂志,2007, 35(11): 979-987.
3
Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension[J]. Eur Respir J, 2024, 64(4): 2401325.
4
Boucly A, Gerges C, Savale L, et al. Pulmonary arterial hypertension[J]. Presse Med, 2023, 52(3): 104168.
5
Barnes PJ. Oxidative stress-based therapeutics in PAH[J]. Redox Biol, 2020, 33: 101544.
6
Ghofrani HA, Gomberg-Maitland M, Zhao L, et al. Mechanisms and treatment of pulmonary arterial hypertension[J]. Nat Rev Cardiol, 2025, 22(2): 105-120.
7
Johnson S, Sommer N, Cox-Flaherty K, et al. Pulmonary hypertension:a contemporary review[J]. Am J Respir Crit Care Med, 2023, 208(5): 528-548.
8
Sahay S, Chakinala MM, Kim NH, et al. Contemporary treatment of pulmonary arterial hypertension: A U.S. perspective[J]. Am J Respir Crit Care Med, 2024, 210(5): 581-592.
9
Mocumbi A, Humbert M, Saxena A, et al. Pulmonary hypertension[J]. Nat Rev Dis Primers, 2024, 10(1): 1.
10
Dixon SJ, Olzmann JA. The cell biology of ferroptosis[J]. Nat Rev Mol Cell Biol, 2024, 25(6): 424-442.
11
Chen L, Min J, Wang F. Copper homeostasis and cuproptosis in health and disease[J]. Signal Transduct Target Ther, 2022, 7(1): 378.
12
Hassoun PM. Pulmonary arterial hypertension[J]. N Engl J Med, 2021, 385(25): 2361-2376.
13
Yang Y, Liang L, Pei W, et al. Interaction of ferroptosis and cuproptosis in the perspective of pulmonary hypertension[J]. Front Cardiovasc Med, 2025, 12: 1611449.
14
Ge Q, Zhang T, Yu J, et al. A new perspective on targeting pulmonary arterial hypertension: programmed cell death pathways (Autophagy, Pyroptosis, Ferroptosis)[J]. Biomed Pharmacother, 2024, 181: 117706.
15
Wang E, Zhou S, Zeng D, Wang R. Molecular regulation and therapeutic implications of cell death in pulmonary hypertension[J]. Cell Death Discov, 2023, 9(1): 239.
16
Mura M, Cecchini MJ, Joseph M, et al. Osteopontin lung gene expression is a marker of disease severity in pulmonary arterial hypertension[J]. Respirology, 2019, 24(11): 1104-1110.
17
Romanoski CE, Qi X, Sangam S, et al. Transcriptomic profiles in pulmonary arterial hypertension associate with disease severity and identify novel candidate genes[J]. Pulm Circ, 2020, 10(4): 2045894020968531.
18
Saygin D, Tabib T, Bittar HET, et al. Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension[J]. Pulm Circ, 2020, 10(1): doi: 10.1177/2045894020908782
19
Luna-López R, Ruiz Martín A, Escribano Subías P. Pulmonary arterial hypertension[J]. Med Clin (Barc), 2022, 158(12): 622-629.
20
Boucherat O, Bonnet S, Provencher S, et al. Anti-remodeling therapies in pulmonary arterial hypertension[J]. Trends Pharmacol Sci, 2025, 46(7): 674-691.
21
任成山,卞士柱,胡明冬. 肺动脉高压的成因及治疗新理念[J/OL]. 中华肺部疾病杂志(电子版) 2023, 16(1): 1-5.
22
Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072.
23
Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications[J]. Cell, 2022, 185(14): 2401-2421.
24
Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease[J]. Nat Rev Mol Cell Biol, 2021, 22(4): 266-282.
25
Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375(6586): 1254-1261.
26
Hu P, Xu Y, Jiang Y, et al. The mechanism of the imbalance between proliferation and ferroptosis in pulmonary artery smooth muscle cells based on the activation of SLC7A11[J]. Eur J Pharmacol, 2022, 928: 175093.
27
Mancias JD, Wang X, Gygi SP, et al. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy[J]. Nature, 2014, 509(7498): 105-109.
28
Ou Y, Wang SJ, Li D, et al. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses[J]. Proc Natl Acad Sci U S A, 2016, 113(44): E6806-E6812.
[1] 张娟敏, 王海, 曹弋娜, 曾欣, 查湘军, 刘莹, 周鸿, 周洋. 响应性纳米平台联合高强度聚焦超声增强三阴乳腺癌铁死亡及免疫治疗的研究[J/OL]. 中华医学超声杂志(电子版), 2026, 23(01): 67-76.
[2] 邓宝, 郭子琳, 仲雷. 乳腺癌治疗中的铁死亡机制与铁基纳米材料应用进展[J/OL]. 中华乳腺病杂志(电子版), 2025, 19(06): 362-368.
[3] 吉宇通, 周月惠, 卫杨文祥, 陈镇秋, 王海彬, 周驰. 滑膜巨噬细胞铁调素诱发软骨细胞铁死亡的机制研究[J/OL]. 中华关节外科杂志(电子版), 2026, 20(03): 322-333.
[4] 王欢, 雷琳, 刘梦瑶, 朱娟娟, 郭王斌. 特发性肺纤维化患者血清LncRNA-GAS5、miR-221-3p与肺动脉高压的相关性研究[J/OL]. 中华危重症医学杂志(电子版), 2025, 18(05): 382-389.
[5] 张春兰, 毛杨, 范会业, 马进. G蛋白信号转导调节因子1与肺动脉高压免疫微环境重塑的跨队列与单细胞研究[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 552-559.
[6] 黄文强, 成俊芬, 庄茜茹. 尾加压素Ⅱ在急性肺栓塞合并肺动脉高压中的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(02): 346-349.
[7] 宋学虎, 骆助林, 谭震, 翁敏. 川芎嗪通过调控SLC7A11/GPX4通路抑制铁死亡减轻小鼠肝纤维化的研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(04): 201-208.
[8] 张弛, 董宇豪, 曹森明, 王闯, 黄燕, 张旭. APR-246通过再激活突变型p53诱导膀胱癌细胞铁死亡与细胞周期阻滞[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(01): 1-12.
[9] 陈艳, 郑升春, 白云凤, 邓蔚竹, 龚娜, 傅一飞, 张紫玥, 邢增辉, 陈香美, 洪权, 孙雪峰. 基于转录组学解析铁死亡相关基因参与恩格列净诱导小鼠远端肾小管细胞p21早期上调[J/OL]. 中华肾病研究电子杂志, 2026, 15(03): 137-143.
[10] 李旭, 乔玉峰. 肾脏缺血再灌注损伤中铁死亡的分子机制及治疗新视角[J/OL]. 中华肾病研究电子杂志, 2026, 15(02): 100-107.
[11] 包文斌, 安晨璐, 常青, 李强, 赵建民. 铁死亡在骨质疏松机制与治疗中的研究进展[J/OL]. 中华老年骨科与康复电子杂志, 2026, 12(03): 180-187.
[12] 张强, 刘媚, 牛娟琴, 陈纲, 岳丽娜, 闫育喜, 贾鹏举, 黄永华, 刘康. 高原肺水肿患者主肺动脉-升主动脉直径比的动态变化及其临床意义[J/OL]. 中华临床医师杂志(电子版), 2026, 20(05): 346-350.
[13] 周懿, 黄容华, 刘政疆. 5-羟色胺与铁死亡介导的脓毒症心肌病的研究进展[J/OL]. 中华临床医师杂志(电子版), 2025, 19(08): 612-617.
[14] 徐凤华, 路童, 朱连连, 王欢, 白黎智, 宋轶, 战丽彬, 路晓光. 大黄附子汤调控SLC7A11/GPX4轴抑制H/R诱导的Caco-2细胞铁死亡的作用研究[J/OL]. 中华卫生应急电子杂志, 2025, 11(06): 380-387.
[15] 马吉辰, 王少松, 王雪飞, 姫旭, 刘桂林. 铁死亡在中医药治疗缺血性脑卒中中的研究进展[J/OL]. 中华脑血管病杂志(电子版), 2026, 20(02): 209-214.
阅读次数
全文


摘要


AI
小
编
AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?